Why Is Integra LifeSciences Holdings (IART) Stock Down -15.48% Today?
Key Takeaways
- Shares of Integra LifeSciences Holdings (IART) fell roughly 15.5% in early trading, dropping from a prior close of $16.09 to about $13.60.
- The sell-off followed a cut to full-year 2026 revenue and adjusted earnings guidance tied to July flooding at its Cincinnati manufacturing facility.
- Preliminary third-quarter results came in below expectations, with adjusted EPS of $0.55–$0.59 on revenue of approximately $410–$412 million.
- The company now expects the flood to reduce fourth-quarter revenue by an additional $15–$20 million, with full manufacturing recovery not expected until the second quarter of 2027.
- Offsetting factors include anticipated insurance recoveries and strong operating cash flow of roughly $190–$200 million for the year.
Opening Summary
Integra LifeSciences Holdings Corporation (IART), a global medical technology company focused on neurosurgery, tissue reconstruction, and specialty surgical products, saw its stock plunge in Friday's session after cutting its full-year 2026 outlook. The shares traded near $13.60, down about 15.5% from the prior session's close of $16.09. The market reaction was driven by preliminary third-quarter results and revised guidance that reflected the ongoing impact of July's flooding at the company's Cincinnati facility.
Guidance Cut Following Cincinnati Facility Flooding
The primary catalyst behind the decline was a downward revision to Integra's full-year financial targets. The company now projects adjusted earnings of $2.30 to $2.40 per share on revenue of $1.634 billion to $1.654 billion, down from its previous guidance of $2.40 to $2.50 per share on revenue of $1.654 billion to $1.695 billion.
The revision stems largely from the July flooding event that damaged portions of the Cincinnati site, including equipment and inventory, and disrupted production of several products within the Specialty Surgical Technologies portfolio. Management estimates the supply disruption reduced third-quarter revenue by approximately $7 million and will reduce fourth-quarter revenue by an additional $15 million to $20 million. A full return to manufacturing operations at the site is not expected until the second quarter of 2027.
Preliminary Third-Quarter Results Fall Short
Alongside the guidance update, Integra provided unaudited preliminary third-quarter results. The company expects adjusted earnings per diluted share of $0.55 to $0.59 on revenue of approximately $410 million to $412 million. The revenue figure came in below what Wall Street had anticipated, adding to investor concerns that the flooding's operational toll will extend well into the coming quarters.
While management emphasized progress in executing business continuity and recovery plans—including use of available inventory and alternate supply sources—the extended recovery timeline weighed on sentiment. Shares responded with an earnings-driven move lower as investors recalibrated expectations for the remainder of the year.
Cash Flow and Insurance Offsets
The sell-off occurred despite several mitigating factors highlighted by the company. Integra expects strong cash generation, including more than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year. Additionally, the company maintains property and business interruption insurance covering the Cincinnati facility and expects insurance recoveries to mitigate a substantial portion of the earnings impact through the recovery period.
Separately, Integra announced the launch of a proposed $600 million seven-year senior secured term loan intended to refinance existing indebtedness, extend maturities, and maintain financial flexibility. While this refinancing supports the company's balance sheet, it did not offset the negative reaction to the weaker operational outlook.
Market Context and Trading Activity
The sharp decline in IART reflected a company-specific catalyst rather than broad market weakness, as investors repriced the stock based on the downwardly revised guidance and a slower-than-hoped recovery timeline. The magnitude of the move indicates elevated selling pressure and heavier-than-normal trading activity relative to the stock's recent daily volumes.
The drop broke through several recent trading levels, pushing the shares well below the $15–$16 range where they had consolidated over the prior week. The move underscores how sensitive the stock remains to operational disruptions at its manufacturing sites and to any revision in forward guidance.
What Comes Next for IART
Investors will now focus on the company's formal third-quarter earnings report and conference call, expected later in October, for additional detail on the recovery timeline and any updates to insurance claims. Key watch points include the pace of production ramp at the Cincinnati facility, the impact on product availability across the Specialty Surgical Technologies portfolio, and whether insurance recoveries materialize as management expects.
Risks remain tilted to the downside, including the possibility of further disruptions, unforeseen recovery costs, and the potential for analyst estimates to be revised lower in response to the reduced guidance. At the same time, the company's strong cash flow outlook and progress on debt refinancing provide a degree of financial cushion as it works through the operational recovery.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. To discover which AI-driven strategies are currently leading the market, visit the Trending AI Robots page today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IART's Stochastic Oscillator slumps into oversold zone
The Stochastic Oscillator for IART moved into oversold territory on October 05, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where IART advanced for three days, in 181 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
IART may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IART as a result. In 75 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for IART turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 32 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IART declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for IART entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. IART’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.213) is normal, around the industry mean (10.853). P/E Ratio (66.483) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.669) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.751) is also within normal values, averaging (39.828).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IART’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices, implants and biomaterials
Industry MedicalNursingServices
Advertisement